AR106453A1 - PROGRAMMABLE UNIVERSAL CELLULAR RECEIVERS AND METHODS TO USE THE SAME - Google Patents

PROGRAMMABLE UNIVERSAL CELLULAR RECEIVERS AND METHODS TO USE THE SAME

Info

Publication number
AR106453A1
AR106453A1 ARP160103236A ARP160103236A AR106453A1 AR 106453 A1 AR106453 A1 AR 106453A1 AR P160103236 A ARP160103236 A AR P160103236A AR P160103236 A ARP160103236 A AR P160103236A AR 106453 A1 AR106453 A1 AR 106453A1
Authority
AR
Argentina
Prior art keywords
pucrs
programmable universal
universal cell
methods
same
Prior art date
Application number
ARP160103236A
Other languages
Spanish (es)
Inventor
T Patterson James
Zhang Yan
Liang Fu Yanwen
Jrg Floris Kaufmann Gunnar
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of AR106453A1 publication Critical patent/AR106453A1/en

Links

Abstract

Receptores celulares universales programables (PUCRs) que comprenden una región del anticuerpo catalítico, un dominio transmembrana y un dominio citoplasmático. Los PUCRs que se divulgan aquí se pueden conjugar a un agente de especificidad para programar el receptor para conferirle especificidad para cualquier molécula de interés. También, ácidos nucleicos que codifican dichos PUCRS, y células que expresan los PUCRs. Dichas células se pueden utilizar para tratar una variedad de condiciones médicas y enfermedades que incluyen al cáncer y enfermedades infecciosas. Reivindicación 24: Una secuencia de ácido nucleico aislada que codifica un receptor celular universal programable, caracterizada porque el receptor celular universal programable comprende una secuencia de aminoácidos según se establece en la SEQ ID Nº 10.Programmable universal cell receptors (PUCRs) comprising a region of the catalytic antibody, a transmembrane domain and a cytoplasmic domain. The PUCRs disclosed herein can be conjugated to a specificity agent to program the receptor to confer specificity on any molecule of interest. Also, nucleic acids encoding said PUCRS, and cells expressing the PUCRs. Such cells can be used to treat a variety of medical conditions and diseases that include cancer and infectious diseases. Claim 24: An isolated nucleic acid sequence encoding a programmable universal cell receptor, characterized in that the programmable universal cell receptor comprises an amino acid sequence as set forth in SEQ ID No. 10.

ARP160103236A 2015-10-23 2016-10-24 PROGRAMMABLE UNIVERSAL CELLULAR RECEIVERS AND METHODS TO USE THE SAME AR106453A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562245978P 2015-10-23 2015-10-23

Publications (1)

Publication Number Publication Date
AR106453A1 true AR106453A1 (en) 2018-01-17

Family

ID=61159873

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103236A AR106453A1 (en) 2015-10-23 2016-10-24 PROGRAMMABLE UNIVERSAL CELLULAR RECEIVERS AND METHODS TO USE THE SAME

Country Status (1)

Country Link
AR (1) AR106453A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113329769A (en) * 2018-10-11 2021-08-31 斯克里普斯研究学院 Antibody compounds with reactive arginine and related antibody drug conjugates

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113329769A (en) * 2018-10-11 2021-08-31 斯克里普斯研究学院 Antibody compounds with reactive arginine and related antibody drug conjugates

Similar Documents

Publication Publication Date Title
UY36961A (en) PROGRAMMABLE UNIVERSAL CELLULAR RECEIVERS AND METHODS TO USE THE SAME
AU2022228122B2 (en) Interleukin-21 muteins and methods of treatment
MX2019000643A (en) Chimeric antigen receptors and methods for use.
MX2020004578A (en) Casz compositions and methods of use.
CL2017002244A1 (en) Specific bispecific antibodies for fap and dr5, specific antibodies for dr5 and methods of use. (divisional application 2829-2015).
CO2017000507A2 (en) Chimeric bcma antigen receptor
MX2019012223A (en) Anti-cd137 antibodies and methods of use thereof.
EA202090931A2 (en) COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING WITH HYBRID PROTEINS
CO2017000510A2 (en) Car constructs
UY35468A (en) CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
WO2016070166A3 (en) Messenger una molecules and uses thereof
PE20170704A1 (en) THERAPEUTIC AGENT INDUCING CYTOTOXICITY
PE20210107A1 (en) ANTI-CD3 ANTIBODIES AND METHODS OF USE
PE20170908A1 (en) VARIANTS OF INTERFERON a2b
EA201790248A1 (en) MEDIA-ANTIBODY COMPOSITIONS AND METHODS FOR THEIR RECEIVING AND APPLICATION
MX2019008346A (en) T cell receptors that bind to ny-eso-1 and methods of use thereof.
EP4273238A3 (en) Compositions comprising polypeptides having xylanase activity and polypeptides having arabinofuranosidase activity
AR084053A1 (en) THERAPEUTIC AGENT THAT INDUCES CYTOTOXICITY
MX2019002903A (en) Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof.
PE20190229A1 (en) ANTI-FCRN ANTIBODIES
PE20230404A1 (en) A CONJUGATE COMPRISING OXYNTOMODULIN AND AN IMMUNOGLOBULIN FRAGMENT, AND USE THEREOF
CO2018012513A2 (en) Antibodies
MX2016012479A (en) Binding members to tnf alpha.
PE20160528A1 (en) ANTIBODIES
CL2017002729A1 (en) Rgma binding protein and its use

Legal Events

Date Code Title Description
FB Suspension of granting procedure